Axial Spondyloarthritis – Forecast in Asia-Pacific Markets to 2028

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

Axial spondyloarthritis (axSpA) is a disease group encompassing both ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA). These conditions are chronic, autoinflammatory disorders of the sacroiliac joints and spine, an area also known as the axial skeleton. The disease is typically diagnosed in young adulthood to middle age (16–45 years) and has a seven- to nine-year delay of diagnosis. The axSpA market has historically been reliant on anti-tumor necrosis factor (TNF) therapies that have been available for over a decade, and the pipeline for drugs in late-stage development was lacking, but recent developments have led to research on novel treatment mechanisms. This will be vital in treating the underdiagnosed nr-axSpA population.
In 2016, Novartis gained approval for Cosentyx (secukinumab), the first-in-class interleukin (IL)-17 inhibitor that was the first new biologic treatment approved for AS that was not an anti-TNF. Moreover, biosimilars of currently marketed anti-TNF biologics such as etanercept, infliximab and adalimumab are also available in Asia-Pacific markets. This is likely to result in a highly competitive market for patients who have failed multiple non-steroidal anti-inflammatory drugs (NSAIDs). Competition will intensify with the arrival of new anti-IL-17 treatments and a new class of therapies in development, Janus kinase (JAK) inhibitors, which will offer a more convenient form of administration. With existing unmet need for all patients, particularly nr-axSpA patients, being diagnosed in a timely manner and having treatment options that are not solely subcutaneously or intravenously administered, axSpA represents an increasingly important rheumatology sector for drug developers.
GlobalData estimates that sales of drugs in the axSpA market were approximately $368.6M in 2018 in the 5GM in Asia-Pacific region. China was the largest market, with approximately $106.5M in drug sales, which represented 28.9% of the total axSpA market. South Korea and Australia contributed $83.5M and $73M in sales respectively, while Japan and India contributed sales of $53.9M and $51.7M respectively in 2018.
APAC sales in the axSpA market are expected to grow $551.6M at a Compound Annual Growth Rate (CAGR) of 4.1% from 20182028. GlobalData forecasts India to grow to $101.4M (18.4% of APAC sales), China to grow to $212.6M (38.5% of APAC sales), Australia to grow to $91M (16.5% of APAC sales), South Korea to grow to $94.6M (17.2% of APAC sales), and Japan to slightly reduce to $52M (9.4% of APAC sales) over the next 10 years.
Key Questions Answered
Over the forecast period, the axSpA market will see the entry of pipeline agents such as the interleukin 17 inhibitors and the JAK inhibitors, the sales of which will offset the loss of sales caused by the entry of biosimilars. How do products compete against each other? Which of these drugs will have the highest peak sales, and why?
Key Opinion Leaders (KOLs) interviewed by GlobalData have indicated that there are several unmet needs within the axSpA indication. What are the main unmet needs in this market? How can the pharmaceutical industry address these needs? To what degree will the therapies under development fulfill these unmet needs?
The axSpA market is likely to become a turbulent space throughout the forecast period and beyond. Which companies are set to be major players in axSpA during the forecast period?

Scope

Overview of axSpA including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.

Annualized axSpA therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2018 and forecast for ten years to 2028.

Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the axSpA therapeutics market.

Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.

Analysis of the current and future market competition in the Asia-Pacific axSpA therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Key Highlights

The greatest driver of growth in the Asia-Pacific axSpA market will be the launches of four pipeline therapies during the forecast period. The entry of these anticipated therapies, including Eli Lilly’s Taltz and Pfizer’s tofacitinib, will be subject to moderate uptake among the AS and nr-axSpA populations.

The main barrier to growth in the axSpA market will be the patent expiry of key marketed products, and subsequent launch of biosimilars of Humira (adalimumab) and the genericization of tofacitinib in the latter half of the forecast across the 5GM.

The most important unmet needs in axSpA are the need for speedier diagnosis and convincing patients to start biologic therapy. The former is being addressed by the increasingly routine use of MRI instead of X-ray to diagnose patients, and the greater understanding and awareness of nr-axSpA. The latter is impacted by poor patient education about their disease and a fear of subcutaneous/intravenous injection.

Factors driving a low biologic therapy treatment rate include some negative or fearful attitudes towards subcutaneously/intravenously administered therapeutics, nr-axSpA patients not perceiving themselves as severe enough to warrant biologic treatment, and a high ACOT for biologic therapies currently on the market and therapies in late-stage development.

Reasons to Buy

The report will enable you to:

Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.

Develop business strategies by understanding the trends shaping and driving the Asia-Pacific axSpA therapeutics market.

Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the Asia-Pacific axSpA therapeutics market in future.

Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

Track drug sales in the Asia-Pacific axSpA therapeutics market from 2018-2028.

Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

AbbVie
Novartis
UCB
Janssen
Eli Lilly
Pfizer
Kyowa Hakko Kirin

Table of Contents

1 Table of Contents

1.1 List of Tables

1.2 List of Figures

2 Axial Spondyloarthritis: Executive Summary

2.1 Axial Spondyloarthritis Market to Experience Mild Growth from 2018–2028

2.2 Late-Stage Pipeline Product Launches Will Result in New Players Establishing Themselves

2.3 Persistent Unmet Needs Will Be Addressed Over the Forecast Period

2.4 Interleukin Inhibitors and Janus Kinase Inhibitors Dominate the Axial Spondyloarthritis Pipeline

2.5 What Do Physicians Think?

3 Introduction

3.1 Catalyst

3.2 Related Reports

3.3 Upcoming Related Reports

4 Disease Overview

4.1 Etiology and Pathophysiology

4.1.1 Etiology

4.1.2 Pathophysiology

4.2 Classification or Staging Systems

5 Epidemiology

5.1 Disease Background

5.2 Risk Factors and Comorbidities

5.3 Global and Historical Trends

5.4 Forecast Methodology

5.4.1 Sources

5.4.2 Forecast Assumptions and Methods, Diagnosed Prevalent Cases of AS – Base Scenario

5.4.3 Forecast Assumptions and Methods, Diagnosed Prevalent Cases of Nr-axSpA – Base Scenario

5.4.4 Forecast Assumptions and Methods, Diagnosed Prevalent Cases of AS – Alternative Scenario

5.4.5 Forecast Assumptions and Methods, Diagnosed Prevalent Cases of Nr-axSpA – Alternative Scenario

5.4.6 Forecast Assumptions and Methods, HLA-B27 Seropositivity Among Diagnosed AS Patients

5.5 Epidemiological Forecast for AS and Nr-axSpA (2018–2028) – Base Scenario

5.5.1 Diagnosed Prevalent Cases of AS

5.5.2 Diagnosed Prevalent Cases of Nr-axSpA

5.6 Epidemiological Forecast for AS and Nr-axSpA (2018–2028) – Alternative Scenario

5.6.1 Diagnosed Prevalent Cases of AS

5.6.2 Age-Specific Diagnosed Prevalent Cases of AS

5.6.3 Sex-Specific Diagnosed Prevalent Cases of AS

5.6.4 Diagnosed Prevalent Cases of AS by HLA-B27 Seropositivity

5.6.5 Diagnosed Prevalent Cases of Nr-axSpA

5.6.6 Age-Specific Diagnosed Prevalent Cases of Nr-axSpA

5.6.7 Sex-Specific Diagnosed Prevalent Cases of Nr-axSpA

5.7 Discussion

5.7.1 Epidemiological Forecast Insight

5.7.2 Limitations of the Analysis

5.7.3 Strengths of the Analysis

6 Disease Management in APAC

6.1 Diagnosis and Treatment Overview

6.2 India

6.3 China

6.4 Australia

6.5 South Korea

6.6 Japan

7 Competitive Assessment

7.1 Overview

7.2 Biosimilars in the AxSpA Market

7.2.1 Marketed Biosimilars

7.2.2 Pipeline Biosimilars

7.2.3 Pricing of Biosimilars Across the 5GM

7.2.4 Uptake of Biosimilars Across the 5GM

8 Unmet Needs and Opportunity Assessment in APAC

8.1 Overview

8.2 Earlier Diagnosis and Treatment

8.2.1 Standardization of Diagnosis

8.2.2 Improved Access to Rheumatologists

8.3 Cost-Effective Therapies

8.4 Patient Compliance to Treatment

8.5 Defined Approach to Selecting Between Anti-TNFs and IL-17 Inhibitors

8.6 Addressing Drug Treatment Failure

9 Pipeline Assessment in APAC

9.1 Overview

9.2 Promising Drugs in Clinical Development

9.2.1 IL-17 Inhibitors

9.2.2 JAK Inhibitors

10 Current and Future Players in APAC

10.1 Overview

10.2 Trends in Corporate Strategy

10.3 AbbVie

10.4 Pfizer

10.5 Johnson & Johnson

10.6 UCB

10.7 Novartis

10.8 Eli Lilly

10.9 Kyowa Hakko Kirin

11 APAC Markets

11.1 Forecast

11.2 Drivers and Barriers

11.3 India

11.3.1 Forecast

11.3.2 Key Events

11.3.3 Drivers and Barriers

11.4 China

11.4.1 Forecast

11.4.2 Key Events

11.4.3 Drivers and Barriers

11.5 Australia

11.5.1 Forecast

11.5.2 Key Events

11.5.3 Drivers and Barriers

11.6 South Korea

11.6.1 Forecast

11.6.2 Key Events

11.6.3 Drivers and Barriers

11.7 Japan

11.7.1 Forecast

11.7.2 Key Events

11.7.3 Drivers and Barriers

12 Appendix

12.1 Bibliography

12.2 Abbreviations

12.3 Methodology

12.3.1 Forecasting Methodology

12.3.2 Diagnosed Patients

12.3.3 Percent Drug-Treated Patients

12.3.4 Drugs Included in Each Therapeutic Class

12.3.5 Launch and Patent Expiry Dates

12.3.6 General Pricing Assumptions

12.3.7 Individual Drug Assumptions

12.3.8 Generic Erosion

12.3.9 Pricing of Pipeline Agents

12.4 Primary Research – KOLs Interviewed for This Report

12.4.1 KOLs

12.5 Primary Research – Prescriber Survey

12.6 About the Authors

12.6.1 Analyst

12.6.2 Reviewer

12.6.3 Therapy Area Directors

12.6.4 Epidemiologist

12.6.5 Managing Epidemiologists

12.6.6 Global Director of Therapy Analysis and Epidemiology

12.6.7 Global Head and EVP of Healthcare Operations and Strategy

12.7 About GlobalData

12.8 Contact Us

12.9 Disclaimer

Table

Table 1: Axial Spondyloarthritis: Key Metrics in the 5GM

Table 2: Risk Factors and Comorbidities for AS

Table 3: Treatment Guidelines for AxSpA

Table 4: Country Profile – India

Table 5: Country Profile – China

Table 6: Country Profile – Australia

Table 7: Country Profile – South Korea

Table 8: Country Profile – Japan

Table 9: Leading Treatments for Axial Spondyloarthritis, 2020

Table 10: Average Percent Discount on Biosimilars Compared to Biologic Reference Products Across the 5GM, 2019

Table 11: AbbVie’s AxSpA Portfolio Assessment, 2020

Table 12: Pfizer’s AxSpA Portfolio Assessment, 2020

Table 13: J&J’s AxSpA Portfolio Assessment, 2020

Table 14: UCB’s AxSpA Portfolio Assessment, 2020

Table 15: Novartis’ AxSpA Portfolio Assessment, 2020

Table 16: Eli Lilly’s AxSpA Portfolio Assessment, 2020

Table 17: Kyowa Hakko Kirin’s AxSpA Portfolio Assessment, 2020

Table 18: Axial Spondyloarthritis Market – APAC Drivers and Barriers, 2018–2028

Table 19: Key Events Impacting Sales for Axial Spondyloarthritis in India, 2018–2028

Table 20: Axial Spondyloarthritis Market – Drivers and Barriers in India, 2018–2028

Table 21: Key Events Impacting Sales for Axial Spondyloarthritis in China, 2018–2028

Table 22: Axial Spondyloarthritis Market – Drivers and Barriers in China, 2018–2028

Table 23: Key Events Impacting Sales for AxSpA in Australia, 2018–2028

Table 24: AxSpA Market – Drivers and Barriers in Australia, 2018–2028

Table 25: Key Events Impacting Sales for Axial Spondyloarthritis in South Korea, 2018–2028

Table 26: AxSpA Market – Drivers and Barriers in South Korea, 2018–2028

Table 27: Key Events Impacting Sales for Axial Spondyloarthritis in Japan, 2018–2028

Table 28: AxSpA Market – Drivers and Barriers in Japan, 2018–2028

Table 29: Key Historical and Projected Launch Dates for Axial Spondyloarthritis

Table 30: Key Historical and Projected Patent Expiry Dates for Axial Spondyloarthritis

Table 31: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

Figures

Figure 1: Global Sales Forecast by Country for Axial Spondyloarthritis in 2018 and 2028

Figure 2: Analysis of the Company Portfolio Gap in Axial Spondyloarthritis During the Forecast Period

Figure 3: Competitive Assessment of the Late-Stage Pipeline Agents That GlobalData Expects to Be Licensed for the Treatment of Axial Spondyloarthritis During the Forecast Period

Figure 4: Pathogenic Mechanisms of Axial Spondyloarthritis

Figure 5: 5GM, Diagnosed Prevalence (%) of AxSpA, Both Sexes, Ages ≥18 Years, 2008–2028 – Base Scenario

Figure 6: 5GM, Sources Used, Diagnosed Prevalent Cases of AS – Base Scenario

Figure 7: 5GM, Sources Used, Diagnosed Prevalent Cases of Nr-axSpA – Base Scenario

Figure 8: 5GM, Sources Used, Diagnosed Prevalent Cases of AS – Alternative Scenario

Figure 9: 5GM, Sources Used, Diagnosed Prevalent Cases of Nr-axSpA – Alternative Scenario

Figure 10: 5GM, Sources Used, HLA-B27 Seropositivity Data Among the Diagnosed Prevalent Cases of AS – Alternative Scenario

Figure 11: 5GM, Diagnosed Prevalent Cases of AS, Ages ≥18 Years, Both Sexes, N, 2018 – Base Scenario

Figure 12: 5GM, Diagnosed Prevalent Cases of Nr-axSpA, Ages ≥18 Years, Both Sexes, N, 2018 – Base Scenario

Figure 13: 5GM, Diagnosed Prevalent Cases of AS, Ages ≥18 Years, Both Sexes, N, 2018 – Alternative Scenario

Figure 14: 5GM, Age-Specific Diagnosed Prevalent Cases of AS, Both Sexes, N, 2018 – Alternative Scenario

Figure 15: 5GM, Sex-Specific Diagnosed Prevalent Cases of AS, Ages ≥18 Years, N, 2018 – Alternative Scenario

Figure 16: 5GM, Diagnosed Prevalent Cases of AS by HLA-B27 Seropositivity, Ages ≥18 Years, Both Sexes, N, 2018 – Alternative Scenario

Figure 17: 5GM, Diagnosed Prevalent Cases of Nr-axSpA, Ages ≥18 Years, Both Sexes, N, 2018 – Alternative Scenario

Figure 18: 5GM, Age-Specific Diagnosed Prevalent Cases of Nr-axSpA, Both Sexes, N, 2018 – Alternative Scenario

Figure 19: 5GM, Sex-Specific Diagnosed Prevalent Cases of Nr-axSpA, Ages ≥18 Years, N, 2018 – Alternative Scenario

Figure 20: Flowchart of the Diagnosis and Management of Axial Spondyloarthritis

Figure 21: Unmet Needs and Opportunities in AxSpA

Figure 22: Overview of the Development Pipeline for AxSpA

Figure 23: Key Phase II/III Trials for the Promising Pipeline Agents that GlobalData Expects to Be Licensed for AxSpA in the Five Growth Markets in Asia-Pacific During the Forecast Period

Figure 24: Competitive Assessment of the Late-Stage Pipeline Agents that GlobalData Expects to Be Licensed for the Treatment of AxSpA in the Five Growth Markets in Asia-Pacific During the Forecast Period

Figure 25: Analysis of the Company Portfolio Gap in AxSpA in the 5GM, During the Forecast Period

Figure 26: APAC (5GM) Sales Forecast by Country for Axial Spondyloarthritis in 2018 and 2028

Figure 27: Sales Forecast by Class for Axial Spondyloarthritis in India in 2018 and 2028

Figure 28: Sales Forecast by Class for Axial Spondyloarthritis in China in 2018 and 2028

Figure 29: Sales Forecast by Class for Axial Spondyloarthritis in Australia in 2018 and 2028

Figure 30: Sales Forecast by Class for Axial Spondyloarthritis in South Korea in 2018 and 2028

Figure 31: Sales Forecast by Class for Axial Spondyloarthritis in Japan in 2018 and 2028

Frequently asked questions

Axial Spondyloarthritis – Forecast in Asia-Pacific Markets to 2028 thematic reports
Currency USD
$8,995

Can be used by individual purchaser only

$26,985

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

Axial Spondyloarthritis – Forecast in Asia-Pacific Markets to 2028 was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Axial Spondyloarthritis – Forecast in Asia-Pacific Markets to 2028 in real time.

  • Access a live Axial Spondyloarthritis – Forecast in Asia-Pacific Markets to 2028 dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.